Journal
CANCER LETTERS
Volume 338, Issue 1, Pages 94-100Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.03.018
Keywords
Pancreatic cancer; Cancer stem cells; Drug resistance; Invasion; Metastasis
Categories
Funding
- National Cancer Institute, NIH [5R01CA083695, 5R01CA108535, 5R01CA132794, 5R01CA131151, 1R01CA15 4321]
- Puschelberg foundation
- Guido foundation
Ask authors/readers for more resources
In the past few years, there have been significant advances in the research on cancer stem cells (CSCs). The emerging evidences have demonstrated that CSCs and epithelial-mesenchymal transition (EMT)-type cells, which share molecular characteristics with CSCs, play critical roles in drug resistance, invasion, and metastasis. Pancreatic cancer (PC) has a high mortality due to both intrinsic (de novo) and extrinsic (acquired) drug resistance, leading to increased invasive and metastatic potential of PC cells. Therefore, targeting pancreatic CSCs and EMT-type cells could be a novel therapeutic strategy for the treatment of PC. In this article, we will review the current state of our knowledge on the role of pancreatic CSCs and EMT-type cells, and summarize the novel therapeutic strategies that could target pancreatic CSCs and EMT-type cells, leading to the reversal of EMT phenotype, the induction of drug sensitivity, and the inhibition of invasion and metastasis of PC, which is expected to yield better treatment outcome. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available